Turning to our international cannabis, we grew net revenue by 22% year over year to approximately $53 million and remained the No. 1 market leader in medical cannabis across Europe. Our annual growth during the fiscal 2024 was driven by increased sales in Germany, Poland, the U.K., Australia, and New Zealand. In Germany, we believe we're best positioned to capture a majority of the expected incremental growth in the cannabis medical market, which is projected to be approximately $3 billion in the medium term. In Canada, our quarter four marked the culmination of transformative year in Canadian cannabis.
It was the highest revenue quarter of the year at $58.8 million, and it marked the completion of our HEXO and Truss Beverages integration, a significant operation overhaul, resulting in extensive improvements in our facility utilization. We continue to lead Canadian cannabis market share by almost 200 bps over the next competitor and have consistently been at the top of the industry for the past three years. From a regional perspective, Tilray was No. 1 across British Columbia, Alberta and Ontario, and Quebec provinces combined, which include over 80% of the Canadian population.
And we've also led in all secondary markets. In Canadian cannabis volume, Tilray shipped approximately 60% more in kgs, reaching 140 metric tons. Our unit sales grew approximately 130% to almost 35 million units. In fiscal 2024, approximately 27% of our Canadian adult-use cannabis net sales revenue came from new innovation, which is a testament to our successful ability to innovate and launch new products.